China gave the greenlight to Eli Lilly & Co.’s blockbuster drug tirzepatide for use in treating diabetes, a move that will ...
SHANGHAI (Reuters) - Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, ...
Eli Lilly’s (NYSE:LLY) weight-loss drug Zepbound (tirzepatide) will remain in short supply through April-end amid increased ...
(Bloomberg) -- Novo Nordisk A/S is shipping more introductory doses of its blockbuster weight-loss drug Wegovy in the US as ...
, opens new tab weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its shares nearly 5%. Lilly said it expects significant production ...
Eli Lilly has seen a surge in demand for its weight-loss drug Zepbound, leading to the company raising its annual sales forecast by $2 billion. The increased demand and manufacturing capacity for ...
Eli Lilly & Co. said Wednesday that two late-stage trials evaluating a 10 mg or 15 mg injection of tirzepatide — the weight-loss drug marketed in the U.S. as Zepbound — reduced the severity of ...
London: Explosive demand and increased manufacturing capacity for Eli Lilly's weight-loss drug Zepbound drove the company to raise its annual sales forecast by $2 billion on Tuesday, lifting its ...
Eli Lily’s weight-loss drug tirzepatide has been shown to “significantly” reduce sleep apnoea severity, the US drugs giant said on Wednesday. The firm said phase 3 clinical trials had showed ...
Eli Lilly (LLY) has reported a better-than-expected first-quarter profit and raised its forward guidance as sales of its popular weight-loss drugs accelerate. The pharmaceutical giant reported ...
We raise our Eli Lilly fair value estimate to $540 from $500 following stronger-than-expected first-quarter results. In particular, pricing drove 10 percentage points of the 26% top-line growth ...